- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00148551
Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
July 26, 2007 updated by: Canadian Retinal Trials Group
Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Eye Care Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Individuals with predominantly classic, subfoveal CNV secondary to AMD.
- No previous PDT Treatment in study eye.
Exclusion Criteria:
- CNV from conditions, other than AMD.
- Other disease that could be responsible for decreased vision.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Changes in visual acuity from baseline.
|
Secondary Outcome Measures
Outcome Measure |
---|
Change in lesion characteristics from baseline.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: David A Maberley, M.D., University of British Columbia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Study Completion (Anticipated)
March 1, 2008
Study Registration Dates
First Submitted
September 6, 2005
First Submitted That Met QC Criteria
September 6, 2005
First Posted (Estimate)
September 8, 2005
Study Record Updates
Last Update Posted (Estimate)
July 30, 2007
Last Update Submitted That Met QC Criteria
July 26, 2007
Last Verified
July 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- 01 (C03 - 0236)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, Italy, Argentina, Spain, United Kingdom, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on Triamcinolone Acetonide
-
Weill Medical College of Cornell UniversityCompletedNail Diseases | Nail PsoriasisUnited States
-
Clearside Biomedical, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis | Noninfectious UveitisUnited States
-
Novartis PharmaceuticalsCompletedAcute Gouty Arthritis FlaresUnited States, Estonia, Lithuania, Germany, Russian Federation, Canada, Australia, Latvia, Ukraine
-
Patel, Rita Vikram, M.D.Ranbaxy Inc.CompletedAcute Steroid Responsive Dermatoses | Chronic Steroid Responsive DermatosesUnited States
-
University of North Carolina, Chapel HillCompletedHidradenitis SuppurativaUnited States
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); AllerganCompletedDiabetic Macular EdemaUnited States
-
Shahid Beheshti University of Medical SciencesCompletedDiabetic Macular EdemaIran, Islamic Republic of
-
SurModics, Inc.CompletedDiabetic Macular EdemaUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknown
-
Edward Hines Jr. VA HospitalUnknown